Video Journal of Oncology (VJOncology)’s Post

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN Blood Cancer J. 2024 Jul 8;14(1):107. doi: 10.1038/s41408-024-01088-6. The GRIFFIN study (NCT02874742) investigated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in newly diagnosed multiple myeloma (NDMM) patients who are eligible for transplant. The study’s final analysis focused on subgroups, including those with high-risk cytogenetic abnormalities (HRCAs). The results showed higher rates of minimal residual disease-negativity with D-RVd compared to RVd in various subgroups, indicating potential benefits of D-RVd in these patients. Key Findings: Higher minimal residual disease-negativity rates with D-RVd in patients ≥ 65 years, with HRCAs, and with gain/amp(1q21) Trend toward improved progression-free survival with D-RVd in patients ≥ 65 years, with HRCAs, and with gain/amp(1q21) Higher grade 3/4 treatment-emergent adverse event rates with D-RVd in patients ≥ 65 years The results suggest that adding daratumumab to RVd may benefit transplant-eligible patients with high-risk NDMM. These findings provide valuable insights for clinical decision-making and potential treatment strategies. https://lnkd.in/gMRYbXtv #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

Breast cancer prevention includes, among others, regular breast self-examination and imaging tests (e.g. mammography). Based on a careful risk assessment, health care providers sometimes recommend drug therapy to reduce the risk of breast cancer in women who are at increased risk. These drugs include selective estrogen receptor modulators (SERMs) such as tamoxifen and raloxifene. They work by blocking the effects of estrogen on breast tissue. These drugs are only effective in preventing cancers that are known to be dependent on female hormones. Another category of drugs that may reduce the risk of breast cancer are aromatase inhibitors (AIs). However, these drugs have not yet received FDA approval for this use. They work by blocking the enzyme (aromatase), which is responsible for the production of estrogen in the body. AIs are contraindicated in women with intact ovarian function. The choice of therapy should be individual and take into account the risk profile of the specific treatment and the patient's preferences. Particular consideration should be given to the risk of thromboembolism, bone mineral density, and the occurrence of menopause. #NeoInsight #Healthcare #BreastCancer #Risk #Cancer #Oncology #OncologyPatient #MedicalResearch #SERM #AI #Mammography

🆕 FDA-approved #GeneTherapy indicated for the treatment of adults with unresectable/ metastatic synovial sarcoma. Synovial sarcoma is a rare form of #cancer in which malignant cells develop & form tumors in the soft tissues of the body. Potentially life-threatening cancers such as #SynovialSarcoma continue to have a devastating impact on individuals, especially those for whom standard treatments have limited efficacy due to tumor growth & progression. The approval of this state-of-the-art immunotherapy technology provides a critical new option for a patient population in need & demonstrates the FDA’s dedication to the advancement of beneficial cancer treatments. Tecelra was approved using the Accelerated Approval pathway, under which the #FDA may approve drugs for serious or life-threatening diseases/ conditions where there is an unmet medical need & the drug is shown to affect a surrogate endpoint that is reasonably likely to predict a clinical benefit to #patients (improving how patients feel or function, or whether they survive longer). This pathway can allow earlier approval while the company conducts further trials to verify the predicted clinical benefit. A confirmatory trial is ongoing to verify Tecelra’s clinical benefit.

March is World Myeloma Action Month. It is a chronic malignant disease of the blood system. Unlike many other types of cancer, it does not manifest itself as a single tumor, but as an accumulation of abnormal plasma cells in the bone marrow and the presence of abnormal protein in the blood. This is a fairly rare cancer, diagnosed most often in elderly people, and the main causes of its occurrence have not yet been identified. Provoking factors may include genetic predisposition, radiation, exposure to toxic chemicals and others. Throughout March, people with myeloma, as well as their families, friends and caregivers, are raising awareness of the disease and advocating for action initiatives. Myeloma disease is diagnosed and treated by a hematologic oncologist, a physician who specializes in malignant neoplasms of the blood. Laboratory and instrumental diagnostic methods, examination and interview of the patient are used to make a diagnosis. Approaches to the treatment of multiple myeloma differ depending on the patient's condition, stage of the disease, etc. Currently, multiple myeloma is completely incurable, but new drugs and modern innovative therapy allow patients to go into long-term remission - this is a huge scientific breakthrough. After basic therapy, periodic check-ups (every 3-6 months) and maintenance therapy are required. To find out more about GCT’s experience in Oncology Clinical Trials you can contact us at bd@gctrials.com. https://lnkd.in/dD4_Ebas   #GCT_awareness #MyelomaActionMonth #Myeloma #Cancer #GCT #GlobalClinicalTrials #CRO #clinicalresearch #drugdevelopment #medicine #pharma #clinicaltrials #clinicaltrial #gctrials #research 

https://lnkd.in/gcdTWvGY #cancerresearch #oncology #endocrinology Summary Long-term survivors of cancer (ie, the patient who is considered cured or for whom the disease is under long-term control and unlikely to recur) are at an increased risk of developing #endocrine #complications such as hypothalamic–pituitary dysfunctions, hypogonadisms, #osteoporosis, or #metabolic #disorders, particularly when intensive tumour-directed therapies are applied. Symptom severity associated with these conditions ranges from mild and subclinical to highly detrimental, affecting individual health and quality of life. Although they are usually manageable, many of these endocrine pathologies remain underdiagnosed and untreated for years. To address this challenge, a higher degree of awareness, standardised screening tools, comprehensible treatment algorithms, and a close collaborative effort between endocrinologists and oncologists are essential to early identify patients who are at risk, and to implement appropriate treatment protocols. This Review highlights common symptoms and conditions related to endocrine disorders among survivors of adult-onset cancer, provides a summary of the currently available practice guidelines, and proposes a practical approach to diagnose affected patients among this group.

🚀 **Breaking Down the Big 3 in 2nd Generation Antiandrogen Therapy: Darolutamide, Enzalutamide, and Apalutamide** 🚀 In the evolving landscape of prostate cancer treatment, understanding the side effects of antiandrogen therapies is crucial for optimizing patient care. Here’s a snapshot of how Darolutamide, Enzalutamide, and Apalutamide stack up: 🔬 **Enzalutamide**: - **Known For**: Fatigue and seizures. - **Insight**: While highly effective, it’s important to monitor for these side effects closely. Patients may need extra support to manage fatigue and ensure seizure risks are addressed. 🌟 **Apalutamide**: - **Known For**: Rash and hypothyroidism. - **Insight**: These side effects require vigilant monitoring. Regular skin checks and thyroid function tests can help mitigate complications and keep treatment on track. 💡 **Darolutamide**: - **Known For**: Minimal drug-drug interactions due to its weak inhibition of CYP3A4. - **Insight**: Ideal for patients needing fewer drug interactions. However, be aware of the need for renal and hepatic dose adjustments. Understanding these nuances helps in tailoring treatment plans and improving patient outcomes. Let’s continue to advance our knowledge and refine our approaches in managing prostate cancer. 🌐 #ProstateCancer #Oncology #Healthcare #Pharmacology #PatientCare #CancerTreatment

My first HCP article is out!!! 😀 I’m thrilled to share my first article on Multiple Myeloma (MM), one of the most prevalent hematological cancers. Through this deep dive, I have explored the critical advancements in MM treatment, with a special focus on CAR-T cell therapy and the revolutionary Ciltacabtagene Autoleucel (CARVYKTI®). In my article, I have covered: 🖊 The evolution of CAR-T cell therapies for MM. 🖊 Mechanism of Ciltacabtagene Autoleucel 🖊 Insights from the CARTITUDE-1 and CARTITUDE-4 studies. 🖊 The potential of CARVYKTI® to extend progression-free survival and improve overall outcomes for MM patients. It has been an incredible learning experience, thanks to Ramesh Mylapilli for the guidance. MedWriters Looking forward to hearing your thoughts and feedback! #MultipleMyeloma #Oncology #CARTcellTherapy #CARVYKTI #Hematology #Pharmacology #MedicalWriting Click on the link below to read full article:

🆕 Hot off the press! 📰 Take a look at our study published in Acta Oncologica examining adverse cardiovascular events in patients with prostate cancer based on treatment. Read the publication here: https://lnkd.in/gai-CBMk #realworlddata #healthcare #prostatecancer #outcomesresearch #HEOR #realworldevidence #RWE #oncology #cancertreatment

#Ribociclib was approved by the FDA for stage II/III ER+ breast cancer in the adjuvant setting in combination with endocrine therapy. This is 2nd CDK4/6 inhibitor in the setting ! Very small benefit shows 5% improvement in DFS at 4 yrs. The differences compared to abemcicilib: 📍3 year duration vs. 2 yrs 📍intermittent 3 weeks on, 1 off, not continuous 📍includes more patients including some with node negative disease 📍less diarrhea than abema, but more neutropenia 📍need for ECG ❤️ monitoring at baseline and at day 15 (cycle 2 ECG no longer needed unless risk factors), need for LFT monitoring (this isn't an insignificant % of pts and needs to be closely watched 👀 ) 📍Lower dose of ribo in adjuvant setting (400mg vs. 600 mg in metastatic, abema dose is the same across early and metastatic) Update was presented #ESMO24 just this week and shows 5% improvement in DFS at 4 yrs. just like #abema the benefit has increased every time we look at updated data.

The latest in ACP #Gastroenterology Monthly: http://ow.ly/EneC50HcMkX 🔸 IV iron appears safe, effective for bleeding-related iron-deficiency anemia in cirrhosis 🔸 GLP-1s associated with lower risk of hepatic decompensation than other diabetes drugs 🔸 Colectomy linked with greater risk of AKI, kidney failure in patients with IBD 🔸 Spotlight on colorectal cancer screening intervals